WHWK vs. FDMT, CADL, LRMR, DRUG, CGC, DMAC, DSGN, OCGN, RNAC, and NGNE
Should you be buying Whitehawk Therapeutics stock or one of its competitors? The main competitors of Whitehawk Therapeutics include 4D Molecular Therapeutics (FDMT), Candel Therapeutics (CADL), Larimar Therapeutics (LRMR), Bright Minds Biosciences (DRUG), Canopy Growth (CGC), DiaMedica Therapeutics (DMAC), Design Therapeutics (DSGN), Ocugen (OCGN), Cartesian Therapeutics (RNAC), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry.
Whitehawk Therapeutics vs. Its Competitors
4D Molecular Therapeutics (NASDAQ:FDMT) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.
Whitehawk Therapeutics has higher revenue and earnings than 4D Molecular Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.
99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 9.6% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Whitehawk Therapeutics has a net margin of 99.42% compared to 4D Molecular Therapeutics' net margin of -594,375.81%. 4D Molecular Therapeutics' return on equity of -40.15% beat Whitehawk Therapeutics' return on equity.
In the previous week, 4D Molecular Therapeutics had 1 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 2 mentions for 4D Molecular Therapeutics and 1 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.88 beat 4D Molecular Therapeutics' score of 0.62 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.
4D Molecular Therapeutics has a beta of 2.83, suggesting that its share price is 183% more volatile than the S&P 500. Comparatively, Whitehawk Therapeutics has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.
4D Molecular Therapeutics presently has a consensus target price of $30.40, suggesting a potential upside of 391.91%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe 4D Molecular Therapeutics is more favorable than Whitehawk Therapeutics.
Summary
4D Molecular Therapeutics beats Whitehawk Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Whitehawk Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for WHWK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding WHWK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Whitehawk Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:WHWK) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access